Skip to content
TrialScanner

NCT04615949

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Phase 2/Phase 3TerminatedCRDLLead

Registry record

Lead sponsor
Cardiol Therapeutics Inc.
Conditions
COVID-19; Cardiovascular Diseases; Cardiovascular Risk Factor
Primary completion
Nov 30, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04615949 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04615949: Cannabidiol in Patients With... | TrialScanner